Get the tools and support you need to best manage your eczema

  • This field is for validation purposes and should be left unchanged.

News

February 21, 2017 — There are dozens of new drugs in development for atopic dermatitis (AD). Late last year, the Food and Drug Administration (FDA) approved the non-steroidal topical treatment, Eucrisa for mild to moderate atopic dermatitis. This March, the FDA is expected to approve dupilumab, the first biologic drug for adults with moderate to […]

Read More


Pain and poor sleep – two symptoms common to people with atopic dermatitis. When these symptoms spin out of control, every part of one’s life is impacted. To find out more about why and how pain and sleep problems affect people with atopic dermatitis, the National Eczema Association funded three studies in these areas as […]

Read More


January 17, 2017 — Biologic drugs have been making headlines as potentially promising new therapies for treating atopic dermatitis (AD). Several have shown positive results in clinical trials and one, dupilumab, is being reviewed for approval by the Food and Drug Administration (FDA) and is expected to come to market in 2017. Biologic medications are […]

Read More


January 17, 2017 — For the first time, ever, the Institute for Clinical and Economic Review (ICER) has begun a process to review the clinical effectiveness and value of two new treatments for atopic dermatitis (AD). ICER is an independent, nonprofit organization that evaluates treatments for serious diseases such as cancer, multiple sclerosis and psoriasis, […]

Read More


January 9. 2017 — Last week, a panel of experts sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) released new guidelines for reducing the risk of peanut allergies in children. This panel, which included National Eczema Association, recommended giving children 6 months and younger peanut-containing foods under the direction of a pediatrician or […]

Read More


By Jennifer Moyer Darr, LCSW, National Jewish Health in Denver, Colorado Children as young as three-years-old begin to notice differences about others (Chernyshov, 2016) and react to these differences. Sometimes, they are just curious and no harm is intended. Sometimes bullying follows. Bullying can occur in the form of verbal, physical, social or psychological taunts […]

Read More


December 20, 2016 — On December 14, the U.S. Food and Drug Administration approved Eucrisa (crisaborole), a topical treatment for children and adults with mild to moderate atopic dermatitis (AD). This marks the first new FDA-approved medication for atopic dermatitis in more than 10 years. “It’s a big deal because for at least 15 years, […]

Read More


December 20, 2016 — This year has been a busy one for eczema research. Currently, there are more than 40 therapies in development for eczema that have the potential to help symptoms such as itch and redness, improve the skin barrier and calm the immune system. Scientists are also looking at how eczema affects the […]

Read More


December 14, 2016 — People with atopic dermatitis have a new treatment option. Today, the U.S. Food and Drug Administration approved Eucrisa (crisaborole), a topical treatment for children and adults with mild to moderate atopic dermatitis (AD). Eucrisa works differently than other topical treatments on the market. It is not a steroid or a topical […]

Read More


December 6, 2016 – NEA’s Chicago Support Group recently hosted a meeting, which included guest speakers Peter A. Lio, MD, NEA Scientific Advisory Committee member and Dr. Richard Aron. Dr. Aron is a South African dermatologist, specializing in Atopic Eczema, and he has created “The Aron Regime.” Following the Chicago event, Dr. Lio shared his […]

Read More